683 Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

683 Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-48,000	Closed	-$1.78M	–	261
2023 Q3	$1.78M	Buy	48,000 +8,000	+20%	+$356K	0.14%	86
2023 Q2	$1.61M	Buy	+40,000	New	+$2.26M	0.12%	99
2022 Q4	–	Sell	-52,000	Closed	-$4.91M	–	311
2022 Q3	$4.91M	Sell	52,000 -29,800	-36%	-$3.35M	0.38%	66
2022 Q2	$15.9M	Buy	81,800 +8,600	+12%	+$1.4M	1.13%	27
2022 Q1	$17M	Buy	73,200 +1,951	+3%	+$621K	0.91%	33
2021 Q4	$28.1M	Hold	71,249	–	–	1.03%	20
2021 Q3	$31.9M	Buy	71,249 +44,142	+163%	+$15.8M	1.24%	20
2021 Q2	$10.5M	Buy	27,107 +18,273	+207%	+$6.52M	0.36%	57
2021 Q1	$3.17M	Hold	8,834	–	–	0.17%	85
2020 Q4	$4.33M	Hold	8,834	–	–	0.21%	75
2020 Q3	$2.86M	Hold	8,834	–	–	0.21%	74
2020 Q2	$3.22M	Buy	+8,834	New	+$2.23M	0.26%	62
2020 Q1	–	Sell	-1,000	Closed	-$412K	–	153
2019 Q4	$412K	Buy	+1,000	New	+$345K	0.05%	85

Other funds holding ATRA

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

683 Capital Management's ATRA Position: Q4 2023 in Review

683 Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 48,000 shares — an estimated $1.78M sold.

683 Capital Management first reported a position in ATRA in Q4 2019 and held it in 13 quarters. The position peaked at $31.9M in Q3 2021. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

683 Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
683 Capital Management sold 48,000 Atara Biotherapeutics shares in Q4 2023, an estimated $1.78M.
683 Capital Management first reported a position in Atara Biotherapeutics in Q4 2019 and held it in 13 quarters.
683 Capital Management's Atara Biotherapeutics position peaked at $31.9M in Q3 2021.
90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on 683 Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.